Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010 (2010), Article ID 343089, 8 pages
http://dx.doi.org/10.1155/2010/343089
Review Article

State-of-the-Art Management of Complications of Myeloma and Its Treatment

1Blood and Marrow Transplant Department, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA

Received 15 October 2009; Accepted 16 March 2010

Academic Editor: Rafat Abonour

Copyright © 2010 Monique A. Hartley-Brown et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. V. Rajkumar, S. Hayman, M. A. Gertz et al., “Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4319–4323, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. S. V. Rajkumar, S. R. Hayman, M. Q. Lacy et al., “Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma,” Blood, vol. 106, no. 13, pp. 4050–4053, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. “APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma,” Clinical Advances in Hematology & Oncology, vol. 1, p. 190, 2003.
  4. M. Attal, J. L. Harousseau, T. Facon et al., “Single versus double autologous stem-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 349, no. 26, pp. 2495–2502, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. I. Jawed, C. M. Lee, J. D. Tward et al., “Survival outcomes for multiple myeloma over three decades: a surveillance, epidemiology, and end results (SEER) analysis,” Journal of Clinical Oncology, vol. 25, no. 18s, 2007, abstract no. 8019. View at Google Scholar
  6. B. G. M. Durie and S. E. Salmon, “A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival,” Cancer, vol. 36, no. 3, pp. 842–854, 1975. View at Google Scholar · View at Scopus
  7. A. D. Clark, A. Shetty, and R. Soutar, “Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma,” Blood Reviews, vol. 13, no. 2, pp. 79–90, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. C. S. Chim, F. K. Li, and K. W. Chan, “Cast nephropathy in multiple myeloma,” Haematologica, vol. 89, no. 4, article e60, 2004. View at Google Scholar · View at Scopus
  9. N. Basić-Jukić, P. Kes, and B. Labar, “Myeloma kidney: pathogenesis and treatment,” Acta medica Croatica, vol. 55, no. 4-5, pp. 169–175, 2001. View at Google Scholar · View at Scopus
  10. A. Arimura, M. I. N. Li, and V. Batuman, “Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury,” Blood, vol. 107, no. 2, pp. 661–668, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. P. W. Sanders, “A new twist in myeloma treatment,” Blood, vol. 107, no. 2, pp. 413–414, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Kanno, H. Okada, H. Nemoto, S. Sugahara, H. Nakamoto, and H. Suzuki, “Crystal nephropathy: a variant form of myeloma kidney—a case report and review of the literature,” Clinical Nephrology, vol. 56, no. 5, pp. 398–401, 2001. View at Google Scholar · View at Scopus
  13. N. Leung, M. A. Gertz, S. R. Zeldenrust et al., “Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains,” Kidney International, vol. 73, no. 11, pp. 1282–1288, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. W. J. Johnson, R. A. Kyle, A. A. Pineda, P. C. O'Brien, and K. E. Holley, “Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy,” Archives of Internal Medicine, vol. 150, no. 4, pp. 863–869, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. W. F. Clark, A. X. Garg, P. G. Blake, G. A. Rock, A. P. Heidenheim, and D. L. Sackett, “Effect of awareness of a randomized controlled trial on use of experimental therapy,” Journal of the American Medical Association, vol. 290, no. 10, pp. 1351–1355, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. C. A. Hutchison, M. Cook, N. Heyne et al., “European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial,” Trials, vol. 9, p. 55, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. M. S. Müller, A. Geibel, H. P. H. Neumann et al., “Primary (AL) amyloidosis in plasma cell disorders,” Oncologist, vol. 11, no. 7, pp. 824–830, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. N. J. Bahlis and H. M. Lazarus, “Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?” Bone Marrow Transplantation, vol. 38, no. 1, pp. 7–15, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. M. Bird, R. Fuge, B. Sirohi et al., “The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study,” British Journal of Haematology, vol. 134, no. 4, pp. 385–390, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. G. G. Glenner, “Amyloid deposits and amyloidosis. The β-fibrilloses. (first of two parts),” The New England Journal of Medicine, vol. 302, no. 23, pp. 1283–1292, 1980. View at Google Scholar · View at Scopus
  21. M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. R. Hayman, and S. Kumar, “Transplantation for amyloidosis,” Current Opinion in Oncology, vol. 19, no. 2, pp. 136–141, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. R. E. Randall, W. C. Williamson Jr., F. Mullinax, M. Y. Tung, and W. J. Still, “Manifestations of systemic light chain deposition,” American Journal of Medicine, vol. 60, no. 2, pp. 293–299, 1976. View at Google Scholar · View at Scopus
  23. B. Ivanyi, “Renal complications in multiple myeloma,” Acta Morphologica Hungarica, vol. 37, no. 3-4, pp. 235–243, 1989. View at Google Scholar · View at Scopus
  24. P. G. Hill, J. M. Forsyth, B. Rai, and S. Mayne, “Serum free light chains: an alternative to the urine bence jones proteins screening test for monoclonal gammopathies,” Clinical Chemistry, vol. 52, no. 9, pp. 1743–1748, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. C. Pozzi, M. D'Amico, G. B. Fogazzi et al., “Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors,” American Journal of Kidney Diseases, vol. 42, no. 6, pp. 1154–1163, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Leung, D. J. Lager, M. A. Gertz, K. Wilson, S. Kanakiriya, and F. C. Fervenza, “Long-term outcome of renal transplantation in light-chain deposition disease,” American Journal of Kidney Diseases, vol. 43, no. 1, pp. 147–153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. M. Oken, C. Pomeroy, D. Weisdorf, and J. M. Bennett, “Prophylactic antibiotics for the prevention of early infection in multiple myeloma,” American Journal of Medicine, vol. 100, no. 6, pp. 624–628, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. S. V. Rajkumar, S. Jacobus, N. Callander et al., “Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 25, no. 18s, 2007, abstract no. LBA8025. View at Google Scholar
  29. J. F. San Miguel, R. Schlag, N. K. Khuageva et al., “Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma,” The New England Journal of Medicine, vol. 359, no. 9, pp. 906–917, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. H. M. Chapel, M. Lee, R. Hargreaves, D. H. Pamphilon, and A. G. Prentice, “Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma,” The Lancet, vol. 343, no. 8905, pp. 1059–1063, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. J. D. Robertson, K. Nagesh, S. N. Jowitt et al., “Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma,” British Journal of Cancer, vol. 82, no. 7, pp. 1261–1265, 2000. View at Google Scholar · View at Scopus
  32. I. Borello, “The immunomodulatory role of lenalidomide on Prevnar® responses in patients with relapsed multiple myeloma: a comprehensive analysis of the immune response,” Blood, vol. 112, p. 2772, 2008. View at Google Scholar
  33. I. Carroll, R. Gaeta, and S. Mackey, “A vaccine to prevent herpes zoster,” The New England Journal of Medicine, vol. 353, no. 13, pp. 1414–1415, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. K. M. Kessler, “A vaccine to prevent herpes zoster,” The New England Journal of Medicine, vol. 353, no. 13, pp. 1414–1415, 2005, author reply. View at Publisher · View at Google Scholar · View at PubMed
  35. M. Vega, “Inhibition of NF-Kb cell signaling and induction of the metastasis suppressor and immune surveillance cancer gene RKIP expression in B-NHL by the novel humanized BM-Ca anti-CD20 monoclonal antibody: implication in chemo and immune-sensitization,” Blood, vol. 112, p. 2613, 2008. View at Google Scholar
  36. R. A. Kyle, “Multiple myeloma. Review of 869 cases,” Mayo Clinic Proceedings, vol. 50, no. 1, pp. 29–40, 1975. View at Google Scholar · View at Scopus
  37. S. D'Sa, N. Abildgaard, J. Tighe, P. Shaw, and M. Hall-Craggs, “Guidelines for the use of imaging in the management of myeloma,” British Journal of Haematology, vol. 137, no. 1, pp. 49–63, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. T. Mahfouz, M. H. Miceli, F. Saghafifar et al., “18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7857–7863, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. J. M. Woolfenden, M. J. Pitt, B. G. M. Durie, and T. E. Moon, “Comparison of bone scintigraphy and radiography in multiple myeloma,” Radiology, vol. 134, no. 3, pp. 723–728, 1980. View at Google Scholar · View at Scopus
  40. D. E. Hughes, K. R. Wright, H. L. Uy et al., “Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo,” Journal of Bone and Mineral Research, vol. 10, no. 10, pp. 1478–1487, 1995. View at Google Scholar · View at Scopus
  41. J. R. Berenson, A. Lichtenstein, L. Porter et al., “Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma,” The New England Journal of Medicine, vol. 334, no. 8, pp. 488–493, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Major, A. Lortholary, J. Hon et al., “Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 558–567, 2001. View at Google Scholar · View at Scopus
  43. C. A. Migliorati, J. Casiglia, J. Epstein, P. L. Jacobsem, M. A. Siegel, and S.-B. Woo, “Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper,” Journal of the American Dental Association, vol. 136, no. 12, pp. 1658–1668, 2005. View at Google Scholar · View at Scopus
  44. S. L. Ruggiero and B. Mehrotra, “Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management,” Annual Review of Medicine, vol. 60, pp. 85–96, 2009. View at Publisher · View at Google Scholar · View at PubMed
  45. J. R. Berenson, B. E. Hillner, R. A. Kyle et al., “American society of clinical oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma,” Journal of Clinical Oncology, vol. 20, no. 17, pp. 3719–3736, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. G. K. Reddy, T. I. Mughal, and G. D. Roodman, “Novel approaches in the management of myeloma-related skeletal complications,” Supportive Cancer Therapy, vol. 4, no. 1, pp. 15–18, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. G. D. Roodman, “Novel targets for myeloma bone disease,” Expert Opinion on Therapeutic Targets, vol. 12, no. 11, pp. 1377–1387, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. G. D. Roodman, “Bone building with bortezomib,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 462–464, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. E. A. N. N. Coleman, S. Coon, J. Hall-Barrow, K. Richards, D. Gaylor, and B. Stewart, “Re: Coleman et al. Feasibility of exercise during treatment for multiple myeloma. Cancer Nursing. 2003;26(5):410–419,” Cancer Nursing, vol. 31, no. 4, pp. 263–264, 2008. View at Google Scholar · View at Scopus
  50. J. Ezzo, B. Berman, V. A. Hadhazy, A. R. Jadad, L. Lao, and B. B. Singh, “Is acupuncture effective for the treatment of chronic pain? A systematic review,” Pain, vol. 86, no. 3, pp. 217–225, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Cotten, N. Boutry, B. Cortet et al., “Percutaneous vertebroplasty: state of the art,” Radiographics, vol. 18, no. 2, pp. 311–320, 1998. View at Google Scholar · View at Scopus
  52. A. Cotten, F. Dewatre, B. Cortet et al., “Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up,” Radiology, vol. 200, no. 2, pp. 525–530, 1996. View at Google Scholar · View at Scopus
  53. I. H. Lieberman, S. Dudeney, M. K. Reinhardt, and G. Bell, “Initial outcome and efficacy of “kyphoplasty” in the treatment of painful osteoporotic vertebral compression fractures,” Spine, vol. 26, no. 14, pp. 1631–1637, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. I. Lieberman and M. K. Reinhardt, “Vertebroplasty and kyphoplasty for osteolytic vertebral collapse,” Clinical Orthopaedics and Related Research, vol. 415, pp. S176–S186, 2003. View at Google Scholar · View at Scopus
  55. L. Karwicki, M. Kmieciak, and M. Kopka, “Surgical treatment of metastasic tumors to long bones in the material of the unit,” Ortopedia Traumatologia Rehabilitacja, vol. 5, no. 3, pp. 358–363, 2003. View at Google Scholar · View at Scopus
  56. G. Srkalovic, M. G. Cameron, L. Rybicki, S. R. Deitcher, K. Kattke-Marchant, and M. A. Hussein, “Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease,” Cancer, vol. 101, no. 3, pp. 558–566, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. R. Baz, L. Li, K. Kottke-Marchant et al., “The role of aspirin in the prevention of thrombotic complication of thalidomide and anthracycline-based chemotherapy for multiple myloma,” Mayo Clinic Proceedings, vol. 80, no. 12, pp. 1568–1574, 2005. View at Google Scholar · View at Scopus
  58. M. Zangari, F. Elice, L. Fink, and G. Tricot, “Thrombosis in multiple myeloma,” Expert Review of Anticancer Therapy, vol. 7, no. 3, pp. 307–315, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp, “Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. M. Zangari, F. Saghafifar, E. Anaissie et al., “Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications,” Blood Coagulation and Fibrinolysis, vol. 13, no. 3, pp. 187–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Palumbo, S. V. Rajkumar, M. A. Dimopoulos et al., “Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma,” Leukemia, vol. 22, no. 2, pp. 414–423, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. A. Palumbo, T. Facon, P. Sonneveld et al., “Thalidomide for treatment of multiple myeloma: 10 years later,” Blood, vol. 111, no. 8, pp. 3968–3977, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. R. Baz, C. Alemany, R. Green, and M. A. Hussein, “Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review,” Cancer, vol. 101, no. 4, pp. 790–795, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. A. Dispenzieri and R. A. Kyle, “Neurological aspects of multiple myeloma and related disorders,” Best Practice and Research: Clinical Haematology, vol. 18, no. 4, pp. 673–688, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. A. A. Argyriou, G. Iconomou, and H. P. Kalofonos, “Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature,” Blood, vol. 112, no. 5, pp. 1593–1599, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. P. G. Richardson, P. Sonneveld, M. W. Schuster et al., “Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline,” British Journal of Haematology, vol. 144, no. 6, pp. 895–903, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. L. Mileshkin, R. Stark, B. Day, J. F. Seymour, J. B. Zeldis, and H. M. Prince, “Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring,” Journal of Clinical Oncology, vol. 24, no. 27, pp. 4507–4514, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. M. A. Dimopoulos, E. Kastritis, and S. V. Rajkumar, “Treatment of plasma cell dyscrasias with lenalidomide,” Leukemia, vol. 22, no. 7, pp. 1343–1353, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. S. Arastu-Kapur, K. Shenk, F. Parlati, and M. K. Bennett, “Non-proteasomal targets of proteasome inhibitors bortezomib and carfilzomib,” in Proceedings of the 5th ASH Annual Meeting and Exposition, 2008, abstract 2657.
  70. L. T. Vlasveld, “Low cobalamin (vitamin BI2) levels in multiple myeloma: a retrospective study,” Netherlands Journal of Medicine, vol. 61, no. 8, pp. 249–252, 2003. View at Google Scholar · View at Scopus
  71. J. Rosenstock, M. Tuchman, L. Lamoreaux, and U. Sharma, “Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial,” Pain, vol. 110, no. 3, pp. 628–638, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. D. Ziegler, M. Hanefeld, K. J. Ruhnau et al., “Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study),” Diabetologia, vol. 38, no. 12, pp. 1425–1433, 1995. View at Publisher · View at Google Scholar · View at Scopus